Signal Genetics Q1 Revenues Slide 41 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Signal Genetics said after the close of the market on Thursday that its first quarter revenues dropped 41 percent year over year. 

The Carlsbad, California-based molecular diagnostics firm recorded $645,000 in revenues for the three months ended March 31, down from $1.1 million in the year-ago quarter. The firm said that the decrease was driven by a drop in the number of tests billed for University of Arkansas for Medical Sciences research and clinical patients at the hospital. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.